May 14th, 2020 | 13:11 CEST
BioNTech, EXMceuticals, Shop Apotheke Europe, Symrise - Shares gaining momentum
Table of contents:
Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.
Emergence of an EU player
The former Goldman Sachs manager Jonathan Summers took over the helm at the young supplier EXMceuticals at the end of 2019. The company focuses on the production of pure ingredients and active ingredients for the healthcare sector.
Medical products have a particularly high standard and the more demanding the market, the higher the margins are usually. Last week, EXMceuticals announced the first buyer, thus attracting the attention of investors. The company is listed on the stock exchanges in Germany and Canada and the share price has already increased.
Healthcare market in transition
EXMceuticals will be established in Europe in the context of a shell acquisition in 2019. From Lisbon in Portugal, the operative business will be implemented and customers will be supplied. The main focus is on the EU. A growth market for pure ingredients extracted from the cannabis plant will gain in importance in the coming years. The European location is particularly exciting in view of the fact that in future the residence and the closeness to the market will be a competitive advantage.
Since COVID-19 at the latest, people in the EU have known how high the dependence on Asian suppliers is. Many an investor in EXMceuticals, with its current market value of around EUR 13 million, recalls the early phase of Symrise, which now has a market capitalization of EUR 13 billion.
Profits with solutions
The companies BioNTech and Shop Apotheke Europe have been among the problem solvers and bearers of hope since the spread of COVID-19 in the investor circles. The shares of these companies have risen accordingly. Shop Apotheke has been particularly in demand in recent months in the context of the supply of drugs and health-related products because of temporary supply bottlenecks in shops or because people did not dare to go out into the streets and the online shop offered an alternative source of supply.
The BioNTech shares benefited from the success reports in connection with the development of a vaccine for COVID-19. The market value of BioNTech is currently USD 11.00 billion and that of Shop Apotheke Europe EUR 1.16 billion.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.